About: Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID‐19
Creator	Nguyen, Cynthia Pitrak, David Pursell, Kenneth Wu, David Pettit, Natasha Kimmig, Lucas Mutlu, Gökhan
source	Medline; PMC
abstract	BACKGROUND: Tocilizumab (TCZ) has been used in the management of COVID‐19‐related cytokine release syndrome (CRS). Concerns exist regarding the risk of infections and drug‐related toxicities. We sought to evaluate the incidence of these TCZ complications among COVID‐19 patients. METHODS: All adult inpatients with COVID‐19 between March 1(st) and April 25(th), 2020 that received TCZ were included. We compared the rate of late‐onset infections (>48 hours following admission) to a control group matched according to intensive care unit admission and mechanical ventilation requirement. Post‐TCZ toxicities evaluated included: elevated liver function tests (LFTs), GI perforation, diverticulitis, neutropenia, hypertension, allergic reactions, and infusion‐related reactions. RESULTS: Seventy‐four patients were included in each group. Seven‐teen infections in the TCZ group (23%) and 6 (8%) infections in the control group occurred >48 hours after admission (p=0.013). Most infections were bacterial with pneumonia being the most common manifestation. Among patients receiving TCZ, LFT elevations were observed in 51%, neutropenia in 1.4%, and hypertension in 8%. The mortality rate among those that received TCZ was greater than the control (39% versus 23%, p=0.03). CONCLUSION: Late onset infections were significantly more common among those receiving TCZ. Combining infections and TCZ‐related toxicities, 61% of patients had a possible post‐TCZ complication. While awaiting clinical trial results to establish the efficacy of TCZ for COVID‐19 related CRS, the potential for infections and TCZ related toxicities should be carefully weighed when considering use. This article is protected by copyright. All rights reserved.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1002/jmv.26429
bibo:pmid	32790075
has license	no-cc
sha1sum (hex)	65e89bd5417506c597e5238e307c826ec98a7b06
schema:url	https://doi.org/10.1002/jmv.26429
resource representing a document's title	Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID‐19
has PubMed Central identifier	PMC7436682
has PubMed identifier	32790075
schema:publication	J Med Virol
resource representing a document's body	covid:65e89bd5417506c597e5238e307c826ec98a7b06#body_text
is schema:about of	named entity 'Safety' named entity 'Tocilizumab' named entity 'COVID-19' named entity 'COMPLICATIONS' named entity 'RISK OF' named entity 'BACKGROUND' named entity 'Onset' named entity 'COVID' named entity 'COVID-19' named entity 'COVID-19' named entity 'AST' named entity 'drug-related' named entity 'autoimmune' named entity 'control groups' named entity 'GI perforation' named entity 'infection rate' named entity 'LFTs' named entity 'follow-up' named entity 'comorbidities' named entity 'monoclonal antibody' named entity 'infection' named entity 'chronic obstructive pulmonary disease' named entity 'clinical protocol' named entity 'chronic kidney disease' named entity 'CRS' named entity 'Tocilizumab' named entity 'ICU' named entity 'LFT' named entity 'COVID-19' named entity 'IL-6' named entity 'diabetes' named entity 'case reports' named entity 'remdesivir' named entity 'lymphoma' named entity 'CRS' named entity 'C-reactive protein' named entity 'end stage renal disease' named entity 'idiopathic' named entity 'GI perforation' named entity 'COVID-19' named entity 'prednisone' named entity 'ferritin' named entity 'hypertension' named entity 'SOC' named entity 'neutropenia' named entity 'symptom' named entity 'infection' named entity 'cytomegalovirus infection' named entity 'corticosteroids' named entity 'cytokine release syndrome' named entity 'inflammatory markers' named entity 'obesity' named entity 'CRS' named entity 'University of Chicago' named entity 'intravenous' named entity 'SOC' named entity 'control group' named entity 'clinical protocol' named entity 'mortality rate' named entity 'patient care' named entity 'COVID' named entity 'increased liver enzymes' named entity 'IL-6 receptor' named entity 'intubation' named entity 'tissue cultures' named entity 'ANC' named entity 'Student's t-test' named entity 'hepatotoxicity' named entity 'nucleic acid amplification test' named entity 'CRS' named entity 'all-cause' named entity 'CT imaging' named entity 'Fisher's exact test' named entity 'off-label' named entity 'control group'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software